Close Menu

NEW YORK – Liquid biopsy firm Biocept has seen its cancer testing activities significantly hamstrung over the last half-year as the COVID-19 pandemic has reduced demand for its suite of single-gene and multi-gene circulating tumor DNA assays and circulating tumor cell tests.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.